Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Ardizzoni

Showing results (41-50 of 369) with videos related to

Pageof 37
Sort By:
Anti-Cancer Drugs|July 7, 2021
Role of PD-L1 assessment in advanced NSCLC: does it still matter?Alessandro Rizzo, Filippo Gustavo Dall'Olio, Annalisa Altimari, et al.
Cancers|April 30, 2021
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting SystemEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
Lung Cancer (Amsterdam, Netherlands)|April 7, 2009
Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case reportMarcello Tiseo, Francesco Gelsomino, Marco Bartolotti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 20, 2013
NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKIFrancesco Facchinetti, Marcello Tiseo, Letizia Gnetti, et al.
Immunotherapy|February 3, 2021
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combinationFrancesco Gelsomino, Francesco Facchinetti, Monia Sisi, et al.
Tumori|May 5, 2010
Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphomaAntonino Musolino, Annamaria Guazzi, Rita Nizzoli, et al.
Critical Reviews in Oncology/Hematology|November 1, 2019
Emerging therapies in malignant pleural mesotheliomaMarika Cinausero, Karim Rihawi, Francesco Cortiula, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 24, 2018
Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 WinsKarim Rihawi, Marika Cinausero, Michelangelo Fiorentino, et al.
Tumori|March 29, 2014
Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case reportPaola Bordi, Marcello Tiseo, Beatrice Bortesi, et al.
Cancers|January 21, 2022
Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous MelanomaFrancesca Comito, Rachele Pagani, Giada Grilli, et al.
Pageof 37

Showing results (41-50 of 369) with videos related to

Sort By:
Pageof 37
Anti-Cancer Drugs|July 7, 2021
Role of PD-L1 assessment in advanced NSCLC: does it still matter?Alessandro Rizzo, Filippo Gustavo Dall'Olio, Annalisa Altimari, et al.
Cancers|April 30, 2021
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting SystemEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
Lung Cancer (Amsterdam, Netherlands)|April 7, 2009
Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case reportMarcello Tiseo, Francesco Gelsomino, Marco Bartolotti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 20, 2013
NSE level in combined neuroendocrine and adenocarcinoma EGFR mutated lung cancer resistant to EGFR-TKIFrancesco Facchinetti, Marcello Tiseo, Letizia Gnetti, et al.
Immunotherapy|February 3, 2021
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combinationFrancesco Gelsomino, Francesco Facchinetti, Monia Sisi, et al.
Tumori|May 5, 2010
Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphomaAntonino Musolino, Annamaria Guazzi, Rita Nizzoli, et al.
Critical Reviews in Oncology/Hematology|November 1, 2019
Emerging therapies in malignant pleural mesotheliomaMarika Cinausero, Karim Rihawi, Francesco Cortiula, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 24, 2018
Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 WinsKarim Rihawi, Marika Cinausero, Michelangelo Fiorentino, et al.
Tumori|March 29, 2014
Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case reportPaola Bordi, Marcello Tiseo, Beatrice Bortesi, et al.
Cancers|January 21, 2022
Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous MelanomaFrancesca Comito, Rachele Pagani, Giada Grilli, et al.
Pageof 37